![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1731741
Àΰø½ÅÀå ½ÃÀå : µð¹ÙÀ̽º À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Åõ¼®º°, Áö¿ªº°(2026-2032³â)Artificial Kidney Market By Device Type (Wearable Artificial Kidney, Implantable Artificial Kidney), By End-user (Hospitals, Specialty Clinics), By Dialysis (Hemodialysis and Peritoneal Dialysis), And Region for 2026-2032 |
Åõ¼®À» ÇÊ¿ä·Î Çϴ ȯÀÚ Áõ°¡ ¿þ¾î·¯ºí Àΰø½ÅÀå, À̽ÄÇü Àΰø½ÅÀå µî ½ÅÀå ´ëü¿ä¹ýÀÇ ±â¼ú ¹ßÀüµµ ½ÃÀå Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àΰø½ÅÀåÀÇ ¿ä±¸´Â 2024³â¿¡ 664¾ï 9,000¸¸ ´Þ·¯¸¦ ³Ñ¾î 2032³â¿¡´Â 6,055¾ï ´Þ·¯¿¡ ´ÞÇÕ´Ï´Ù.
¶ÇÇÑ ½ÅÀå À̽ÄÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ½ÅÈï ±¹°¡ÀÇ ÀÇ·á ÀÎÇÁ¶ó°¡ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ´Ù¾çÇÑ »ê¾÷¿¡¼ Àΰø ½ÅÀåÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, 2026-2032³â 35.08%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Àΰø½ÅÀå ½ÃÀå Á¤ÀÇ/°³¿ä
Àΰø½ÅÀåÀº Åõ¼®±â¶ó°íµµ ºÒ¸®¸ç, Ç÷¾×³» ³ëÆó¹°°ú °úµµÇÑ ¼öºÐÀ» °É·¯ ü³» ÀüÇØÁú ±ÕÇüÀ» À¯ÁöÇÏ°í µ¶¼Ò ÃàÀûÀ» ¹æÁöÇÏ´Â µî õ¿¬ ½ÅÀåÀÇ ±âº»ÀûÀÎ ±â´ÉÀ» ¼öÇàÇÏ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ÁÖ¿ä ¿ëµµ´Â ¸¸¼º ½ÅÀåÁúȯ ¹× ±Þ¼º ½ÅºÎÀü Ä¡·á·Î, ½ÅÀå À̽ÄÀ» ¹ÞÀ» ¼ö ¾ø´Â ȯÀÚ¿¡°Ô »ý¸í À¯Áö¸¦ À§ÇÑ ½ÅÀå ´ëü¿ä¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÇâÈÄ »ý¸í°øÇÐ ¹× ³ª³ëÅ×Å©³î·¯ÁöÀÇ ¹ßÀüÀ¸·Î º¸´Ù È¿À²ÀûÀ̰í ÈÞ´ë °¡´ÉÇÑ Àΰø ½ÅÀåÀÌ °³¹ßµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, »ýü °øÇÐÀûÀ¸·Î ¼³°èµÈ Àå±â, ¿¬¼Ó Åõ¼® Ä¡·á¸¦ Á¦°øÇÏ´Â ¿þ¾î·¯ºí ±â±â µîÀÇ ±â¼ú Çõ½ÅÀÌ ÀÌ·ç¾îÁú °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¸¸¼ºÄáÆÏº´(CKD)ÀÇ À¯º´·ü Áõ°¡¿Í ºñ¿ë È¿À²ÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î Àΰø½ÅÀå ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)¿¡ µû¸£¸é ¹Ì±¹¿¡¼´Â ¾à 3,700¸¸ ¸íÀÇ ¼ºÀÎÀÌ CKD¸¦ ¾Î°í ÀÖÀ¸¸ç, ¼ö¹é¸¸ ¸íÀÌ CKDÀÇ À§Çè¿¡ ³ëÃâµÇ¾î ÀÖ´Ù°í ÇÕ´Ï´Ù. ÀÇ·á ȯ°æÀÌ °¡Ä¡ ±â¹Ý ÀÇ·á·Î ÀüȯµÊ¿¡ µû¶ó ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ½ÅÀå À̽ÄÀ̳ª Àå±â ÀÔ¿ø¿¡ µû¸¥ °íºñ¿ë ¾øÀÌ È¿°úÀûÀÎ Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ ¼Ö·ç¼ÇÀ» Á¡Á¡ ´õ ¸¹ÀÌ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½ÅÀåÁúȯÀÇ °æÁ¦Àû ºÎ´ãÀ¸·Î ÀÎÇØ º¸´Ù Á¢±ÙÇϱ⠽¬¿î Ä¡·á¹ý¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³´ç´¢º´-¼Òȱâ-½ÅÀ庴 ¿¬±¸¼Ò(NIDDK)ÀÇ º¸°í¿¡ µû¸£¸é ¸»±â ½ÅºÎÀü(ESRD) ȯÀÚÀÇ Åõ¼®¿¡ ¼Ò¿äµÇ´Â ¿¬°£ ºñ¿ëÀº ȯÀÚ 1Àδç 9¸¸ ´Þ·¯°¡ ³ÑÀ» ¼ö ÀÖÀ¸¸ç, ȯÀÚ¿Í ÀÇ·á ½Ã½ºÅÛ ¸ðµÎ¿¡ Å« °æÁ¦Àû ºÎ´ãÀÌ µÇ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. µû¶ó¼ Ä¡·á ºñ¿ëÀ» Àý°¨Çϰí È¿À²À» ³ôÀÌ´Â Àΰø½ÅÀå ±â¼úÀÇ Çõ½ÅÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¿½Ã¿¡ ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ºÎÀÀÇϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù.
µ¥ÀÌÅÍ º¸¾È°ú ÇÁ¶óÀ̹ö½Ã ¹®Á¦´Â ƯÈ÷ ±â¼ú ¹ßÀüÀ¸·Î µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀÌ ÀÇ·á±â±â¿Í ÅëÇյʿ¡ µû¶ó Àΰø ½ÅÀå ½ÃÀåÀÇ ¼ºÀå¿¡ Áß¿äÇÑ µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. Àΰø½ÅÀå, ƯÈ÷ ¿ø°ÝÀÇ·á Ç÷§ÆûÀ̳ª ¸ð´ÏÅ͸µ ½Ã½ºÅÛ·Î ¿¬°áµÈ Àΰø½ÅÀåÀº °Ç° µ¥ÀÌÅÍ¿Í Ä¡·á ±â·ÏÀ» Æ÷ÇÔÇÑ ¹Î°¨ÇÑ È¯ÀÚ Á¤º¸¸¦ ¼öÁýÇϰí Àü¼ÛÇÕ´Ï´Ù. ÇコÄÉ¾î ºÐ¾ß¿¡¼ÀÇ »çÀ̹ö °ø°Ý°ú µ¥ÀÌÅÍ À¯ÃâÀÇ ºóµµ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ Á¤º¸°¡ ¾Ç¿ëµÉ °¡´É¼º¿¡ ´ëÇÑ °æ°è½ÉÀÌ ³ô¾ÆÁö¸é¼ ȯÀÚ¿Í ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀÇ µµÀÔÀ» ÁÖÀúÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ ¹Ì±¹ÀÇ ÀǷẸÇè »óÈ£¿î¿ë¼º ¹× Ã¥ÀÓ¿¡ °üÇÑ ¹ý·ü(HIPAA)°ú °°Àº ¾ö°ÝÇÑ µ¥ÀÌÅÍ º¸È£ ±ÔÁ¦·Î ÀÎÇØ Á¦Á¶¾÷ü´Â ¾ÈÀüÇÑ ±â¼ú°ú ÄÄÇöóÀ̾𽺠Á¶Ä¡¿¡ ¸¹Àº ÅõÀÚ¸¦ ÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ º¹À⼺°ú ºñ¿ë Áõ°¡´Â ƯÈ÷ Áß¼Ò±â¾÷ÀÇ °æ¿ì, Àΰø½ÅÀå °³¹ß ¹× º¸±ÞÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á ºÐ¾ß¿¡¼ ȯÀÚÀÇ ½Å·Ú°¡ °¡Àå Áß¿äÇÑ ¸¸Å, °·ÂÇÑ µ¥ÀÌÅÍ º¸È£ Á¶Ä¡¿Í Åõ¸íÇÑ °üÇàÀ» ÅëÇØ ÀÌ·¯ÇÑ º¸¾È ¹®Á¦¸¦ ÇØ°áÇÏ´Â °ÍÀº Àΰø½ÅÀå ±â¼ú¿¡ ´ëÇÑ ½Å·Ú¸¦ Çü¼ºÇÏ°í ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» º¸ÀåÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
The increasing number of patients requiring dialysis. Technological advancements in kidney replacement therapies, such as wearable and implantable artificial kidneys, are also driving innovation in the market. The need for artificial kidney is surpassing USD 66.49 Billion in 2024 and reaching USD 605.5 Billion by 2032.
Additionally, the growing awareness of the benefits of kidney transplantation and the expanding healthcare infrastructure in emerging economies contribute to market expansion. These factors contribute to the increasing use of artificial kidney in a variety of industries is expected to grow at a CAGR of 35.08% about from 2026 to 2032.
Artificial Kidney Market: Definition/ Overview
An artificial kidney, also known as a dialysis machine, is a medical device that performs the essential functions of a natural kidney by filtering waste products and excess fluids from the blood, thereby maintaining the body's electrolyte balance and preventing the accumulation of toxins. Its primary application is in the treatment of individuals with chronic kidney disease or acute kidney injury, providing life-sustaining renal replacement therapy for patients who cannot undergo kidney transplantation. Looking to the future, advancements in biotechnology and nanotechnology hold promise for the development of more efficient and portable artificial kidneys, potentially leading to innovations such as bioengineered organs and wearable devices that offer continuous dialysis treatment, significantly enhancing patients' quality of life and reducing the need for traditional dialysis sessions.
The increasing prevalence of chronic kidney disease (CKD) and the growing demand for cost-effective treatment options are significantly propelling the artificial kidney market. According to the Centers for Disease Control and Prevention (CDC), approximately 37 million adults in the United States have CKD, and millions more are at risk. As the healthcare landscape shifts towards value-based care, healthcare providers are increasingly seeking affordable solutions that can deliver effective treatment without the high costs associated with kidney transplants or prolonged hospital stays.
Furthermore, the economic burden of kidney diseases necessitates the need for more accessible treatment options. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reported that the annual cost of dialysis for patients with end-stage renal disease (ESRD) can exceed $90,000 per patient, underscoring the financial strain on both patients and healthcare systems. As a result, innovations in artificial kidney technologies, aimed at reducing treatment costs and enhancing efficiency, are essential to meet the rising demand for affordable healthcare solutions while improving patient outcomes.
Data security and privacy concerns pose significant challenges to the growth of the artificial kidney market, particularly as advancements in technology integrate digital health solutions with medical devices. Artificial kidneys, especially those connected to telemedicine platforms or monitoring systems, collect and transmit sensitive patient information, including health data and treatment history. The increasing frequency of cyberattacks and data breaches in healthcare raises alarms about the potential misuse of this information, which can deter patients and healthcare providers from adopting these innovative solutions.
Moreover, stringent regulations regarding data protection, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States, require manufacturers to invest heavily in secure technology and compliance measures. This added layer of complexity and cost can slow down the development and deployment of artificial kidneys, particularly for smaller companies. As patient trust is paramount in healthcare, addressing these security concerns through robust data protection measures and transparent practices will be crucial for fostering confidence in artificial kidney technologies and ensuring sustained market growth.
The rising adoption of wearable devices is expected to significantly boost the artificial kidney market by enhancing patient engagement and facilitating remote monitoring of kidney health. Wearable technologies, such as smartwatches and health trackers, are increasingly being integrated with advanced monitoring systems that can provide real-time data on vital signs, fluid balance, and kidney function. This integration empowers patients to take an active role in managing their health, leading to timely interventions and improved outcomes.
Moreover, the growing trend of telemedicine and remote patient monitoring is driving demand for wearable artificial kidneys, as healthcare providers seek efficient ways to manage chronic conditions without the need for frequent hospital visits.
The implantable artificial kidney segment is the fastest-growing segment, driven by advancements in bioengineering and materials science that aim to create devices capable of mimicking natural kidney functions more effectively.
The widespread availability of advanced technologies in hospitals is significantly fueling the artificial kidney market by enhancing the efficiency and effectiveness of renal care. Innovations such as portable dialysis machines, automated systems, and remote monitoring capabilities are making it easier for healthcare providers to deliver high-quality care.
These advancements enable hospitals to offer more comprehensive treatment options, reducing the need for patients to seek alternatives, which in turn drives demand for artificial kidneys. Moreover, the integration of artificial intelligence and data analytics into renal care is improving patient outcomes through personalized treatment plans and real-time monitoring of patient health.
Specialty Clinics is the fastest-growing segment, driven by the increasing trend towards outpatient care and the desire for more personalized treatment options.
Country/Region-wise
Technological advancements in North America are poised to significantly drive the expansion of the artificial kidney market. Innovations such as miniaturization of dialysis devices, the integration of artificial intelligence for personalized treatment, and the development of wearable dialysis systems are enhancing the accessibility and efficiency of renal replacement therapies. According to the U.S. Renal Data System, as of 2021, over 786,000 individuals were undergoing dialysis in the United States, and advancements in technology could help meet the growing demand for more effective and convenient treatment options.
Moreover, the increasing investment in research and development, alongside supportive government initiatives, is further propelling market growth. The National Institutes of Health (NIH) reported funding of approximately $690 million in 2022 for kidney disease research, which aims to foster innovations in artificial kidneys and improve patient outcomes. Such financial backing, combined with the rising prevalence of chronic kidney disease-projected to affect about 37 million adults in the U.S. by 2030-underscores the vital role of technological progress in shaping the future of the artificial kidney market.
The increasing number of well-equipped hospitals in the Asia Pacific region is expected to significantly propel the artificial kidney market. As healthcare infrastructure improves, more hospitals are investing in advanced medical technologies, including dialysis machines and artificial kidney devices. According to the World Bank, the number of hospitals in the Asia Pacific region has grown by approximately 20% from 2010 to 2020, reflecting the region's commitment to enhancing healthcare services. This growth not only increases access to treatment for patients with chronic kidney disease but also encourages the adoption of advanced dialysis technologies, thereby expanding the artificial kidney market.
Furthermore, government initiatives aimed at improving healthcare access and the growing prevalence of kidney-related disorders are driving demand for artificial kidneys. The Asia Pacific region accounted for nearly 50% of global end-stage renal disease cases in 2021, as reported by the Global Burden of Disease Study. With an aging population and lifestyle-related health issues on the rise, the need for artificial kidneys is expected to surge. Coupled with the expanding hospital infrastructure, this demand presents a lucrative opportunity for manufacturers and healthcare providers, reinforcing the positive outlook for the artificial kidney market in the region.
The competitive landscape of the artificial kidney market is characterized by a mix of established players and emerging startups, each focusing on innovative features such as real-time tracking, integration with IoT devices, and user-friendly interfaces. Companies are increasingly investing in research and development to enhance product offerings and improve customer service, creating a dynamic and rapidly evolving market environment.
Some of the prominent players operating in the artificial kidney market include:
Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., DaVita Inc., NIPRO Medical Corporation, Nikkiso Co., Ltd., Fresenius Medical Care AG & Co. KGaA, Baxter, Merit Medical Systems, Medtronic, Xcorporeal, Inc.
In August 2024 Reistone Biopharma reported significant progress in its clinical trials for an innovative artificial kidney that utilizes bioengineered materials to mimic natural kidney function. Preliminary results have shown promising outcomes in terms of biocompatibility and efficacy, paving the way for future regulatory approvals. The company aims to revolutionize renal replacement therapy by providing a more efficient and long-lasting solution for patients with chronic kidney disease.
In July 2024 Dialyze Direct announced the expansion of its home dialysis services, integrating artificial kidney technology into their offerings. This initiative aims to provide patients with greater flexibility and comfort by enabling them to manage their treatment at home. The company is focused on enhancing patient education and support to ensure successful adoption of these advanced technologies in home settings.
In June 2024 Xeltis unveiled groundbreaking results from its research on bioengineered kidneys, which utilize a unique combination of synthetic and biological materials to promote kidney regeneration. The company's innovative approach aims to create a functional artificial kidney that not only replaces lost function but also encourages tissue regeneration.